Aurora Cannabis (TSX: ACB), CanniMed Therapeutics (TSX: CMED), and CTT Pharmaceutical Holdings (OTC: CTTH) have entered into a three-way agreement that will provide Aurora Cannabis the exclusive rights to distribute CTT Pharmaceuticals patented cannabinoid delivery technology.
The six patents received by Aurora are related to cannabinoid delivery for pain management that will use sublingual wafers to deliver the benefits of medicinal cannabinoids to patients.
The “Orally Dissolvable Thin Film” wafers are a patented delivery mechanism that allows cannabinoids to be delivered directly into the blood stream by dissolving into the capillaries underneath your tongue.
The benefits include:
- ODF Wafer is taken orally but does not require water or swallowing
- ODF Wafers dissolve quickly in the oral cavity (5-15 seconds), with the active ingredient rapidly absorbed and diffused for direct access to the bloodstream.
- The active ingredient, once absorbed, can bypass the liver’s first-pass effect, improving therapeutic outcomes and efficacy through improved bioavailability and facilitates excellent patient compliance.
- ODF Wafers are suitable for a wide range of patients, including for geriatric and pediatric patients who experience difficulty swallowing.
The three companies are working towards gaining approval from Health Canada for legal distribution.